MDM2 and neoplasm: In addition to being a prognostic indicator for patient survival, S100B itself contributes to tumor progression when overexpressed by acting on several molecular targets including p53, Hdm2, HdmX, and the p90 ribosomal S6 kinase (RSK) [8–12].